Krista L Lentine1, David Axelrod, Christina Klein, Christopher Simpkins, Huiling Xiao, Mark A Schnitzler, Janet E Tuttle-Newhall, Vikas R Dharnidharka, Daniel C Brennan, Dorry L Segev. 1. 1 Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO. 2 Division of Abdominal Transplantation, Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO. 3 Division of Abdominal Transplantation, Department of Surgery, Dartmouth Hitchcock Medical Center, Hanover, NH. 4 Transplant Nephrology, Washington University School of Medicine, St. Louis, MO. 5 Division of Abdominal Transplantation, Department of Surgery, Johns Hopkins University, Baltimore, MD. 6 Address correspondence to: Krista L. Lentine, M.D., Ph.D., Saint Louis University Center for Outcomes Research, Salus Center 4th Floor, 3545 Lafayette Ave, St. Louis, MO 63104.
Abstract
BACKGROUND: Descriptions of the sequelae of ABO-incompatible (ABOi) kidney transplantation are limited to single-center reports, which may lack power to detect important effects. METHODS: We examined U.S. Renal Data System registry data to study associations of ABOi live-donor kidney transplantation with clinical complications in a national cohort. Among 14,041 Medicare-insured transplants in 2000 to 2007, 119 non-donor-A2 ABOi transplants were identified. A2-incompatible (n=35) transplants were categorized separately. Infection and hemorrhage events were identified by diagnosis codes on billing claims. Associations of ABO incompatibility with complications were assessed by multivariate Cox regression. RESULTS: Recipients of ABOi transplants experienced significantly (P<0.05) higher incidence of wound infections (12.7% vs. 7.3%), pneumonia (7.6% vs. 3.8%), and urinary tract infections (UTIs) or pyelonephritis (24.5% vs. 15.3%) in the first 90 days compared with ABO-compatible recipients. In adjusted models, ABO incompatibility was associated with twice the risk of pneumonia (adjusted hazard ratio [aHR], 2.22; 95% confidence interval [CI], 1.14-4.33) and 56% higher risk of UTIs or pyelonephritis (aHR, 1.56; 95% CI, 1.05-2.30) in the first 90 posttransplantation days, and 3.5 times the relative risk of wound infections in days 91 to 365 (aHR, 3.55; 95% CI, 1.92-6.57). ABOi recipients, 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of early hemorrhage (aHR, 1.96; 95% CI, 1.19-3.24). A2-incompatible transplantation was associated only with early risk of UTIs or pyelonephritis. CONCLUSION: ABOi transplantation offers patients with potential live donors an additional transplant option but with higher risks of infectious and hemorrhagic complications. Awareness of these complications may help improve protocols for the management of ABOi transplantation.
BACKGROUND: Descriptions of the sequelae of ABO-incompatible (ABOi) kidney transplantation are limited to single-center reports, which may lack power to detect important effects. METHODS: We examined U.S. Renal Data System registry data to study associations of ABOi live-donor kidney transplantation with clinical complications in a national cohort. Among 14,041 Medicare-insured transplants in 2000 to 2007, 119 non-donor-A2 ABOi transplants were identified. A2-incompatible (n=35) transplants were categorized separately. Infection and hemorrhage events were identified by diagnosis codes on billing claims. Associations of ABO incompatibility with complications were assessed by multivariate Cox regression. RESULTS: Recipients of ABOi transplants experienced significantly (P<0.05) higher incidence of wound infections (12.7% vs. 7.3%), pneumonia (7.6% vs. 3.8%), and urinary tract infections (UTIs) or pyelonephritis (24.5% vs. 15.3%) in the first 90 days compared with ABO-compatible recipients. In adjusted models, ABO incompatibility was associated with twice the risk of pneumonia (adjusted hazard ratio [aHR], 2.22; 95% confidence interval [CI], 1.14-4.33) and 56% higher risk of UTIs or pyelonephritis (aHR, 1.56; 95% CI, 1.05-2.30) in the first 90 posttransplantation days, and 3.5 times the relative risk of wound infections in days 91 to 365 (aHR, 3.55; 95% CI, 1.92-6.57). ABOi recipients, 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of early hemorrhage (aHR, 1.96; 95% CI, 1.19-3.24). A2-incompatible transplantation was associated only with early risk of UTIs or pyelonephritis. CONCLUSION: ABOi transplantation offers patients with potential live donors an additional transplant option but with higher risks of infectious and hemorrhagic complications. Awareness of these complications may help improve protocols for the management of ABOi transplantation.
Authors: J F Whiting; R S Woodward; E Y Zavala; D S Cohen; J E Martin; G G Singer; J A Lowell; M R First; D C Brennan; M A Schnitzler Journal: Transplantation Date: 2000-09-15 Impact factor: 4.939
Authors: Christian Morath; Luis Eduardo Becker; Albrecht Leo; Jörg Beimler; Katrin Klein; Jörg Seckinger; Lars Philipp Kihm; Peter Schemmer; Stephan Macher-Goeppinger; Markus Wahrmann; Georg A Böhmig; Gerhard Opelz; Caner Süsal; Martin Zeier; Vedat Schwenger Journal: Transplantation Date: 2012-04-27 Impact factor: 4.939
Authors: Mark A Schnitzler; Krista L Lentine; Adrian Gheorghian; David Axelrod; Digisha Trivedi; Gilbert L'Italien Journal: Transpl Int Date: 2011-12-22 Impact factor: 3.782
Authors: F C Renner; B Czekalinska; B Kemkes-Matthes; A Feustel; W A Stertmann; W Padberg; R Weimer Journal: Transplant Proc Date: 2010-12 Impact factor: 1.066
Authors: Krista L Lentine; Lisa A Rocca Rey; Swathy Kolli; Giuliana Bacchi; Mark A Schnitzler; Kevin C Abbott; Huiling Xiao; Daniel C Brennan Journal: Clin J Am Soc Nephrol Date: 2008-04-02 Impact factor: 8.237
Authors: Jeong Kye Hwang; Sang Il Kim; Bum Soon Choi; Cheol Woo Yang; Yong Soo Kim; In Sung Moon; Ji Il Kim Journal: J Korean Surg Soc Date: 2011-07-11
Authors: Krista L Lentine; Bertram L Kasiske; Andrew S Levey; Patricia L Adams; Josefina Alberú; Mohamed A Bakr; Lorenzo Gallon; Catherine A Garvey; Sandeep Guleria; Philip Kam-Tao Li; Dorry L Segev; Sandra J Taler; Kazunari Tanabe; Linda Wright; Martin G Zeier; Michael Cheung; Amit X Garg Journal: Transplantation Date: 2017-08 Impact factor: 4.939
Authors: Vikas R Dharnidharka; Mark A Schnitzler; Jiajing Chen; Daniel C Brennan; David Axelrod; Dorry L Segev; Kenneth B Schechtman; Jie Zheng; Krista L Lentine Journal: Transpl Int Date: 2016-09-28 Impact factor: 3.782
Authors: Vikas R Dharnidharka; Abhijit S Naik; David Axelrod; Mark A Schnitzler; Huiling Xiao; Daniel C Brennan; Dorry L Segev; Henry Randall; Jiajing Chen; Bertram Kasiske; Krista L Lentine Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Abhijit S Naik; Vikas R Dharnidharka; Mark A Schnitzler; Daniel C Brennan; Dorry L Segev; David Axelrod; Huiling Xiao; Lauren Kucirka; Jiajing Chen; Krista L Lentine Journal: Transpl Int Date: 2015-12-09 Impact factor: 3.782
Authors: D Axelrod; D L Segev; H Xiao; M A Schnitzler; D C Brennan; V R Dharnidharka; B J Orandi; A S Naik; H Randall; J E Tuttle-Newhall; K L Lentine Journal: Am J Transplant Date: 2016-02-08 Impact factor: 8.086
Authors: Kyle R Jackson; Jennifer D Motter; Amber Kernodle; Niraj Desai; Alvin G Thomas; Allan B Massie; Jacqueline M Garonzik-Wang; Dorry L Segev Journal: Am J Transplant Date: 2020-03-12 Impact factor: 8.086